Jef­frey Kindler’s Cen­trex­ion spells out pos­i­tive da­ta for its PhI­II-ready pain drug

The re­search team at Cen­trex­ion Ther­a­peu­tics, a Boston-based biotech start­up led by ex-Pfiz­er CEO Jef­frey Kindler, turned up at a sci­en­tif­ic con­fer­ence in Eu­rope to spell out their Phase IIb da­ta for a new pain drug the com­pa­ny is de­vel­op­ing for os­teoarthri­tis.

Their lead drug is CN­TX-4975, which tar­gets the TR­PV1 re­cep­tor and is aimed at de­ac­ti­vat­ing pain fibers that send pain sig­nals from the knee straight to the brain. That way a sin­gle shot should work for six months out, un­til the fibers re­gen­er­ate to start flash­ing those sig­nals again.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER